☆ 4.6 Meeting Abstract

Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

JOURNAL OF THORACIC ONCOLOGY (2016)

Get Full Text
Add to Collection

Journal

JOURNAL OF THORACIC ONCOLOGY
Volume 11, Issue 4, Pages S115-S115

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1556-0864(16)30246-5

Keywords

-

Categories

Oncology Respiratory System

Funding

  1. AstraZeneca

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.